Literature DB >> 10626918

Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis.

J M Davis1, P G Janicak, D M Hogan.   

Abstract

OBJECTIVE: To determine by meta-analysis the efficacy of mood stabilizers in preventing recurrence of bipolar or unipolar mood disorders and to consider the evidence for a lithium withdrawal-induced relapse syndrome.
METHOD: Controlled studies of lithium, valproate and carbamazepine in preventing future episodes of affective disorders were classified according to methodological rigour, and meta-analyses were performed overall and on each type.
RESULTS: A total of 19 blinded, randomized, controlled trials of prophylaxis in 865 patients found lithium highly effective (74% recurrence on placebo vs. 29% on lithium). In the mirror-image studies, whose substantial lithium vs. prior treatment difference cannot be explained by withdrawal relapse, lithium reduced relapse by 50% (bipolar) and 58%(unipolar).
CONCLUSION: Maintenance lithium produces a highly significant reduction in relapses. The mirror-image studies had not been systematically analysed previously, and they support the effectiveness of lithium. We also failed to find sufficient evidence to prove that the lithium-withdrawal relapse phenomenon exists.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626918     DOI: 10.1111/j.1600-0447.1999.tb10890.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  16 in total

1.  Diagnosis and management of patients with bipolar disorder in primary care.

Authors:  Michael Berk; Seetal Dodd; Lesley Berk; Jane Opie
Journal:  Br J Gen Pract       Date:  2005-09       Impact factor: 5.386

Review 2.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 3.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

4.  Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.

Authors:  Rachael W Taylor; Lindsey Marwood; Emanuella Oprea; Valeria DeAngel; Sarah Mather; Beatrice Valentini; Roland Zahn; Allan H Young; Anthony J Cleare
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

Review 5.  Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis.

Authors:  Eduard Vieta; Marc Valentí
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

6.  Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder.

Authors:  Christopher Baethge; Philipp Gruschka; Michael N Smolka; Anne Berghöfer; Tom Bschor; Bruno Müller-Oerlinghausen; Michael Bauer
Journal:  J Psychiatry Neurosci       Date:  2003-09       Impact factor: 6.186

Review 7.  Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach.

Authors:  Giovanni A Fava; Chiara Ruini; Nicoletta Sonino
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

8.  The history of lithium therapy.

Authors:  Edward Shorter
Journal:  Bipolar Disord       Date:  2009-06       Impact factor: 6.744

Review 9.  Bipolar disorder.

Authors:  John R Geddes; David Briess
Journal:  BMJ Clin Evid       Date:  2007-08-01

10.  Carbamazepine extended-release capsules in bipolar disorder.

Authors:  Richard H Weisler
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.